阿尔茨海默病生物标志物的种族差异评估
本研究纳入1255名参与者(173名非洲裔美国人),分析阿尔茨海默病分子生物标志物的种族差异。结果显示,在报告痴呆家族史的个体中,非洲裔美国人的海马总体积较低,且脑脊液总tau和磷酸化tau181浓度显著低于白人,并存在显著的种族与APOE ε4交互作用。结论提示阿尔茨海默病生物标志物分析应校正种族因素。
要点
- 非洲裔美国人脑脊液总tau和磷酸化tau181浓度显著低于白人。
- 种族差异仅见于APOE ε4阳性参与者,存在显著交互作用。
- 有痴呆家族史者中,非洲裔美国人海马体积低于白人。
核心结论
- 阿尔茨海默病分子生物标志物分析应校正种族因素。
- 非洲裔美国人脑脊液总tau和磷酸化tau181较低,可能反映种族与APOE ε4的交互作用。
研究设计与样本
- 纵向研究纳入1255名参与者(173名非洲裔美国人),2004年1月1日至2015年12月31日入组于华盛顿大学Knight阿尔茨海默病研究中心。
- 参与者完成脑磁共振成像和/或匹兹堡化合物B正电子发射断层扫描和/或脑脊液淀粉样β42、总tau、磷酸化tau181检测。
- 采用方差分析或协方差分析进行横断面分析,校正年龄、性别、教育水平、种族、APOE ε4状态和临床状态。
主要发现
- 非洲裔美国人67.1%(116/173)认知正常,非西班牙裔白人66.9%(724/1082)认知正常。
- 脑磁共振成像缺血性病灶频率、匹兹堡化合物B平均皮层标准化摄取值比、脑脊液淀粉样β42浓度均无种族差异。
- 在有痴呆家族史的个体中,非洲裔美国人平均海马总体积低于白人(6418.26 [138.97] vs 6990.50 [44.10] mm3)。
- 非洲裔美国人脑脊液总tau平均浓度低于白人(293.65 [34.61] vs 443.28 [18.20] pg/mL;P < .001)。
- 非洲裔美国人脑脊液磷酸化tau181平均浓度低于白人(53.18 [4.91] vs 70.73 [2.46] pg/mL;P < .001)。
关键数值与推荐
- 脑脊液总tau和磷酸化tau181存在显著种族与APOE ε4交互作用,仅APOE ε4阳性参与者显示种族差异。
临床怎么用
- 解读阿尔茨海默病分子生物标志物时需考虑种族因素。
- 对非洲裔美国人进行生物标志物评估时,应结合APOE ε4状态解读tau相关指标。
局限性
- 本研究为观察性横断面分析,不能确定因果关系。
- 非洲裔美国人样本量相对较小(173人)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms. OBJECTIVE: To ascertain whether there are racial disparities in molecular biomarkers for Alzheimer disease. DESIGN, SETTING, AND PARTICIPANTS: A total of 1255 participants (173 African Americans) were enrolled from January 1, 2004, through December 31, 2015, in longitudinal studies at the Knight Alzheimer Disease Research Center at Washington University and completed a magnetic resonance imaging study of the brain and/or positron emission tomography of the brain with Pittsburgh compound B (radioligand for aggregated amyloid-β) and/or cerebrospinal fluid (CSF) assays for the concentrations of amyloid-β42, total tau, and phosphorylated tau181. Independent cross-sectional analyses were conducted from April 22, 2016, to August 27, 2018, for each biomarker modality with an analysis of variance or analysis of covariance including age, sex, educational level, race, apolipoprotein E (APOE) ε4 allele status, and clinical status (normal cognition or dementia). All biomarker assessments were conducted without knowledge of the clinical status of the participants. MAIN OUTCOMES AND MEASURES: The primary outcomes were hippocampal volumes adjusted for differences in intracranial volumes, global cerebral amyloid burden as transformed into standardized uptake value ratios (partial volume corrected), and CSF concentrations of amyloid-β42, total tau, and phosphorylated tau181. RESULTS: Of the 1255 participants (707 women and 548 men; mean [SD] age, 70.8 [9.9] years), 116 of 173 African American participants (67.1%) and 724 of 1082 non-Hispanic white participants (66.9%) had normal cognition. There were no racial differences in the frequency of cerebral ischemic lesions noted on results of brain magnetic resonance imaging, mean cortical standardized uptake value ratios for Pittsburgh compound B, or for amyloid-β42 concentrations in CSF. However, in individuals with a reported family history of dementia, mean (SE) total hippocampal volumes were lower for African American participants than for white participants (6418.26 [138.97] vs 6990.50 [44.10] mm3). Mean (SE) CSF concentrations of total tau were lower in African American participants than in white participants (293.65 [34.61] vs 443.28 [18.20] pg/mL; P < .001), as were mean (SE) concentrations of phosphorylated tau181 (53.18 [4.91] vs 70.73 [2.46] pg/mL; P < .001). There was a significant race by APOE ε4 interaction for both CSF total tau and phosphorylated tau181 such that only APOE ε4-positive participants showed the racial differences. CONCLUSIONS AND RELEVANCE: The results of this study suggest that analyses of molecular biomarkers of Alzheimer disease should adjust for race. The lower CSF concentrations of total tau and phosphorylated tau181 in African American individuals appear to reflect a significant race by APOE ε4 interaction, suggesting a differential effect of this Alzheimer risk variant in African American individuals compared with white individuals.
引用
- Morris JC, Schindler SE, McCue LM, et al. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurol. 2019. PMID: 30615028. doi:10.1001/jamaneurol.2018.4249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。